Chemoinformaics analysis of 2,3,5-Trihydroxybenzoic acid
| Molecular Weight | 170.12 | nRot | 1 |
| Heavy Atom Molecular Weight | 164.072 | nRig | 7 |
| Exact Molecular Weight | 170.022 | nRing | 1 |
| Solubility: LogS | -1.136 | nHRing | 0 |
| Solubility: LogP | 1.055 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 18 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 6 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 7 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 6 |
| nHA | 4 | APOL | 19.7008 |
| nHD | 4 | BPOL | 6.88724 |
| QED | 0.363 |
| Synth | 2.142 |
| Natural Product Likeliness | 1.162 |
| NR-PPAR-gamma | 0.091 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.005 |
| HIA | 0.042 |
| CACO-2 | -5.719 |
| MDCK | 0.00000434 |
| BBB | 0.081 |
| PPB | 0.617484 |
| VDSS | 0.465 |
| FU | 0.288482 |
| CYP1A2-inh | 0.026 |
| CYP1A2-sub | 0.068 |
| CYP2c19-inh | 0.029 |
| CYP2c19-sub | 0.043 |
| CYP2c9-inh | 0.157 |
| CYP2c9-sub | 0.106 |
| CYP2d6-inh | 0.014 |
| CYP2d6-sub | 0.129 |
| CYP3a4-inh | 0.036 |
| CYP3a4-sub | 0.024 |
| CL | 12.245 |
| T12 | 0.952 |
| hERG | 0.021 |
| Ames | 0.025 |
| ROA | 0.071 |
| SkinSen | 0.871 |
| Carcinogencity | 0.028 |
| EI | 0.874 |
| Respiratory | 0.338 |
| NR-Aromatase | 0.005 |
| Antiviral | No |
| Prediction | 0.859715 |